Thus, given the accumulation of fibronectin aggregates inside lesions of MS patients [12], the use of modified-anti-sulfatide antibodies may represent a promising therapeutic tool to foster endogenous remyelination. This evidence concerns the gene FN1 and myeloid sarcoma.